ClinicalTrials.gg

Retinitis Pigmentosa clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 280 studies for Retinitis Pigmentosa across more than 10 countries. 74 are recruiting or about to start. 221 of them are mainly about Retinitis Pigmentosa (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its narrower condition Usher Syndromes too: 287 studies, 77 open.

Status

Completed
119
Recruiting
49
Active, not recruiting
34
Status unknown
27
Not yet recruiting
20
Terminated
18

Phase

Phase 2
76
Phase 1
69
Phase 3
21
Early Phase 1
7
Phase 4
1

Where

United States
119
France
40
Germany
30
United Kingdom
29
China
18
Canada
17

Who develops what

Add Retinitis Pigmentosa to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 8 programs from 8 companies, 5 with this as their studies’ main aim; 2 with a live phase 3 study; 1 primary completion in the next 12 months. Compare Bayer, Laboratoires Thea and Sumitomo Pharma here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
RTX-015☆ Track1 live phase-3 study: NCT07901751Ray Therapeutics, Inc.

The 1 in phase 3 with the nearest primary completion, of 8 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.human retinal progenitor cells · jCyte, Inc · Phase 2 main aimNCT06912633 Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP) — primary endpoint: Safety of Intravitreal Injection of 6.0M jCell · 31 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Retinitis Pigmentosa studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Coming up

27studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 49 Retinitis Pigmentosa studies recruiting now, 37 (76%) set no upper age limit and 7 (14%) stop at 75 or younger. 16 (33%) take children under 18. 0 (0%) are for women only and 2 (4%) for men only; 10 (20%) take healthy volunteers.

Recruiting studies that take each age, of 49
AgeWomenMen
1012 (24%)14 (29%)
1846 (94%)48 (98%)
3047 (96%)49 (100%)
4047 (96%)49 (100%)
5047 (96%)47 (96%)
6546 (94%)46 (94%)
7542 (86%)42 (86%)
8541 (84%)41 (84%)

Across all 280 studies, recruiting or not: 25% stop at 75 or younger and 16% at 65; 31% take children; <1% are for women only and 3% for men only; 14% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Retinitis Pigmentosa studies take

Of 28 phase 1/2 interventional studies under Retinitis Pigmentosa, half reached primary completion within 53 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 1/253 mo22–92 · 28 studies——
Interventional, no phase42 mo21–154 · 30 studies——
Observational76 mo28–… · 48 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 280. Browse all 280 → or search them.